

# Major R&D Pipeline: 3 ADCs

As of October 2020



## Phase 1

**U3-1402** (JP/US)  
HER3+BC

**DS-8201** (US/EU)  
BC, bladder cancer  
(nivolumab combo)

**U3-1402** (JP/US/EU/Asia)  
NSCLC


**DS-8201** (US/EU)  
BC, NSCLC (pembrolizumab  
combo)

**DS-1062** (JP/US)  
NSCLC, TNBC

**DS-8201** (US/EU/Asia)  
HER2+ GC combo, 2L~/1L  
DESTINY-Gastric03

**DS-1062** (JP/US)  
NSCLC (without actionable  
mutation, pembrolizumab  
combo)  
TROPION-Lung02

## Phase 2

**DS-8201** (JP/US/EU)  
HER2+/m NSCLC  
DESTINY-Lung01 

**DS-8201** (JP/US/EU)  
HER2+ CRC  
DESTINY-CRC01

**DS-8201** (US/EU)  
HER2+GC, 2L  
DESTINY-Gastric02

**DS-8201** (US/EU/Asia)  
NSCLC (durvalumab combo)  
HUDSON

**DS-8201** (US/EU/Asia)  
TNBC (durvalumab combo)  
BEGONIA

**DS-8201** (US/Asia) prep  
HER2 expressing tumors  
DESTINY-PanTumor02

**U3-1402** (JP/US/EU)  
HER3 CRC

## Phase 3



**DS-8201** (JP/US/EU/Asia)  
HER2+BC, 3L  
DESTINY-Breast02

**DS-8201** (JP/US/EU/Asia)  
HER2+BC, 2L  
DESTINY-Breast03

**DS-8201** (JP/US/EU/Asia)  
HER2 low BC, 3L~  
DESTINY-Breast04

**DS-8201** (JP/US/EU/Asia)  
HER2 low BC, chemo naive  
DESTINY-Breast06

## Submitted

**DS-8201** (US)  
HER2+GC, 3L  
DESTINY-Gastric01  

**DS-8201** (EU)  
HER2+BC, 3L  
DESTINY-Breast01



DS-8201 HER2-directed ADC

DS-1062 TROP2-directed ADC

U3-1402 HER3-directed ADC

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer

 project in oncology that is planned to be submitted for approval based on the results of phase 2 trials

 Breakthrough Designation (US), SAKIGAKE Designation (JP)  Orphan drug designation (JP/US/EU)

# Major R&D Pipeline: Alpha

As of October 2020



## Phase 1

## Phase 2

## Phase 3

## Submitted

<b>DS-7300</b> (JP/US) B7-H3-directed ADC Solid tumors	<b>DS-3201</b> (JP/US) EZH1/2 inhibitor Non-Hodgkin's Lymphomas (PTCL)	<b>DS-1647 (G47Δ)</b> (JP) Oncolytic HSV-1 Malignant glioma IIS	<b>Quizartinib</b> (JP/US/EU/Asia) FLT3 inhibitor AML, 1L	<b>Axicabtagene ciloleucel</b> <b>Axi-Cel™</b> (JP) Anti CD19 CAR-T cells R/R B-cell lymphoma
<b>DS-6157</b> (JP/US) GPR20-directed ADC GIST	<b>DS-3201</b> (US) EZH1/2 inhibitor AML, ALL	<b>DS-3201</b> (JP) EZH1/2 inhibitor ATL/L	<b>Prasugrel</b> (JP) ADP receptor inhibitor Ischemic stroke	<b>VN-0107/MEDI3250</b> (JP) live attenuated influenza vaccine nasal spray
<b>DS-1055</b> (JP/US) Anti-GARP antibody Solid tumors	<b>PLX2853</b> (US) BET inhibitor AML	<b>DS-1001</b> (JP) Mutant IDH1 inhibitor Glioma	<b>Mirogabalin</b> (JP/Asia) $\alpha_2\delta$ Ligands Central neuropathic pain	<b>Edoxaban</b> (JP) FXa inhibitor AF in the very elderly
<b>DS-2741</b> (JP) Anti-Orai1 antibody Atopic dermatitis	<b>PLX2853</b> (US) BET inhibitor Solid tumor	<b>DS-5141</b> (JP) ENA oligonucleotide DMD	<b>Esaxerenone</b> (JP) MR blocker Diabetic nephropathy	
	<b>DS-1211</b> (US) TNAP inhibitor Pseudoxanthoma elasticum		<b>VN-0102/JVC-001</b> (JP) Measles mumps rubella combined vaccine	

Oncology

Specialty medicine

Vaccine

AF: atrial fibrillation, ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, DMD: Duchenne muscular dystrophy, GIST: gastrointestinal stromal tumor, IIS: investigator-initiated study, NSCLC: non-small cell lung cancer, PTCL: peripheral T-cell lymphoma

: project in oncology that is planned to be submitted for approval based on the results of phase 2 trials

: SAKIGAKE Designation (JP) : Orphan drug designation (JP/US/EU)